Amivantamab-associated capillary leak syndrome presenting with severe anasarca and profound hypoalbuminaemia in metastatic non-small cell lung cancer
- 1Internal Medicine Daycare, Ben-Gurion University of the Negev, Be’er Sheva, Israel
- 2Ben-Gurion University of the Negev, Be’er Sheva, Israel
- 3Family Medicine, Ben-Gurion University of the Negev, Be’er Sheva, Israel
Abstract
Amivantamab, a bispecific EGFR–MET (Epidermal Growth Factor-Mesenchymal-Epithelial Transition Factor) antibody, is increasingly used in advanced non-small cell lung cancer (NSCLC) and is associated with MET-related adverse events, including peripheral oedema and hypoalbuminamia. We report the case of a woman in her early 70s with metastatic EGFR-positive NSCLC who developed rapidly progressive anasarca, acute kidney injury and profound hypoalbuminaemia immediately after the first dose of amivantamab. Extensive evaluation excluded cardiac failure, nephrotic syndrome, hepatic disease, protein-losing enteropathy, infection, autoimmune disease, plasma cell dyscrasia and tumour progression. Discontinuation of amivantamab and treatment with scheduled intravenous albumin combined with loop diuretics resulted in complete clinical and biochemical recovery, sustained at 6-month follow-up while continuing osimertinib. This case represents a severe manifestation of amivantamab-associated fluid retention and supports the recognition of a drug-induced capillary leak phenotype.
Related
- Capillary hemangioma of the breast presenting as a new mass on screening mammography: A case report with imaging-pathology correlation
- Cardiac Capillary Hemangioma in a Patient Presenting with Syncope: Report of a Case and Systematic Review of the Literature
- Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup
- Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced Infusion-Related Reaction
- Sjögren’s Syndrome-Associated Medium- and Large-Vessel Vasculitis Presenting With Acute Abdominal Symptoms
BibTeX
@article{bartal2026amivantamabassociated,
title = {{Amivantamab-associated capillary leak syndrome presenting with severe anasarca and profound hypoalbuminaemia in metastatic non-small cell lung cancer}},
author = {Carmi Bartal and Julia Dudnik and Aya Biderman},
journal = {BMJ Case Reports},
year = {2026},
month = oct,
doi = {10.1136/bcr-2026-274132},
url = {https://doi.org/10.1136/bcr-2026-274132},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Amivantamab-associated capillary leak syndrome presenting with severe anasarca and profound hypoalbuminaemia in metastatic non-small cell lung cancer
AU - Carmi Bartal
AU - Julia Dudnik
AU - Aya Biderman
PY - 2026
DA - 2026/10/29
JO - BMJ Case Reports
DO - 10.1136/bcr-2026-274132
UR - https://doi.org/10.1136/bcr-2026-274132
AB - Amivantamab, a bispecific EGFR–MET (Epidermal Growth Factor-Mesenchymal-Epithelial Transition Factor) antibody, is increasingly used in advanced non-small cell lung cancer (NSCLC) and is associated with MET-related adverse events, including peripheral oedema and hypoalbuminamia. We report the case of a woman in her early 70s with metastatic EGFR-positive NSCLC who developed rapidly progressive anasarca, acute kidney injury and profound hypoalbuminaemia immediately after the first dose of amivantamab. Extensive evaluation excluded cardiac failure, nephrotic syndrome, hepatic disease, protein-losing enteropathy, infection, autoimmune disease, plasma cell dyscrasia and tumour progression. Discontinuation of amivantamab and treatment with scheduled intravenous albumin combined with loop diuretics resulted in complete clinical and biochemical recovery, sustained at 6-month follow-up while continuing osimertinib. This case represents a severe manifestation of amivantamab-associated fluid retention and supports the recognition of a drug-induced capillary leak phenotype.
SN - 1757-790X
ER -